Longeveron (LGVN) Debt Ratio (2021 - 2023)

Longeveron's (LGVN) quarterly Debt Ratio came in at 0.05 in Q3 2023, up 49.07% quarter-over-quarter from 0.03 in Q2 2023.

Longeveron (LGVN) Debt Ratio (2021 - 2023) Analysis & Trends

Longeveron's Debt Ratio history runs 3 years deep, the most recent figure standing at 0.05 for Q3 2023.

  • On a quarterly basis, Debt Ratio changed N/A year-over-year to 0.05 in Q3 2023; TTM through Sep 2023 was 0.05, a N/A change from a year earlier, with the FY2022 full-year figure at 0.02, up 63.85% from the prior year.
  • Debt Ratio grew to 0.05 in Q3 2023 per LGVN's latest filing, from 0.03 in the prior quarter.
  • Across five years, Debt Ratio topped out at 0.05 in Q3 2023 and bottomed at 0.01 in Q4 2021.
  • The 3-year median for Debt Ratio is 0.03 (2023), against an average of 0.03.
  • Biggest YoY gain for Debt Ratio was 63.85% in 2022; the steepest drop was 63.85% in 2022.
  • Year by year, Debt Ratio stood at 0.01 in 2021, then soared by 63.85% to 0.02 in 2022, then jumped by 145.01% to 0.05 in 2023.
  • Per Business Quant, the three latest LGVN Debt Ratio figures stand at 0.05 (Q3 2023), 0.03 (Q2 2023), and 0.03 (Q1 2023).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt Ratio (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - 1.41
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 0.11
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 0.05
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Longeveron 3.97 Mn -11.79 Mn 264,000.00 -

Historic Data

Download Data
DateValue
Sep 30, 2023 0.05
Jun 30, 2023 0.03
Mar 31, 2023 0.03
Dec 31, 2022 0.02
Dec 31, 2021 0.01